NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
Journal of Clinical Oncology · 20.02.2026 · 44 (6) · 497-507
DOI: 10.1200/jco-25-00929 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2026. Verfasst von Van K Morris und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas-MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Ipilimumab, Nivolumab, Anus Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE In the previously completed NCI9673 (part A) single-arm study, the antiprogrammed death (PD)–ligand-1 antibody nivolumab demonstrated efficacy for patients with metastatic anal cancer. In NCI9673 (Part B), we evaluated the anticytotoxic T-cell lymphocyte antigen-4 (CTLA-4) antibody ipilimumab in combination with nivolumab for patients with incurable anal cancer. METHODS In this phase II NCI ETCTN trial, 100 patients with refractory, incurable anal cancer were randomly assigned to receive nivolumab (480 mg IV once every 4 weeks) alone or with ipilimumab (1 mg/kg IV once every 8 weeks). The primary end point was progression-free survival (PFS). Secondary endpoints included radiographic response, overall survival (OS), and grade ≥3 adverse events. A log-rank test was used to compare survival between arms, with a one-sided alpha of 0.1 and power of 90%. Immune biomarkers were analyzed from baseline and on treatment tissue and blood collections. RESULTS The median PFS for nivolumab versus nivolumab plus ipilimumab were 2.9 months (90% CI, 1.9 to 3.8) and 3.7 months (90% CI, 2.0 to 5.6), respectively (hazard ratio [HR], 0.86 [95% CI, 0.60 to 1.23]; P = .25). Response rates were similar for nivolumab (17.4%) and nivolumab plus ipilimumab (21.5%; P = .89). The median OS was 15.9 months for nivolumab and 20.0 months for nivolumab plus ipilimumab (HR, 0.98 [90% CI, 0.63 to 1.51]). Grade ≥3 treatment-related AEs occurred in 6 patients (12%) receiving nivolumab alone and in 12 patients (25%) receiving nivolumab plus ipilimumab. At week 9, circulating TIGIT+ CD8 + cells ( P < .001) increased with nivolumab plus ipilimumab treatment relative to baseline. CONCLUSION The addition of ipilimumab to nivolumab did not statistically improve overall response rate, PFS, or OS but may harbor increased toxicity. Paired blood samples identified TIGIT expression on peripheral T cells as a compensatory change unique to dual PD-1 plus CTLA-4 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Texas-MD Anderson Cancer Center, Houston, TX.
- Vanderbilt-Ingram Cancer Center, Nashville, TN.
- University of Chicago, Chicago, IL.
- Georgetown University, Washington, DC.
- University of Michigan, Ann Arbor, MI.
- The Ohio State University, Columbus, OH.
ORCID-Profile: Van K Morris, Kristen K Ciombor, Joshua K Ochieng, Blase Polite, Benjamin A Weinberg, John C Krauss, Sarbajit Mukherjee, Syma Iqbal, Tony Shields, Al B Benson, Syed Kazmi, Christopher Lieu, Howard Hochster, Jennifer Whisenant, Cara Haymaker, Cathy Eng
Förderung
- NCI NIH HHS
Zitieren
APA
Morris, V. K., Ciombor, K. K., Xiao, L., Ochieng, J. K., Marmonti, E., Polite, B., Weinberg, B. A., Krauss, J. C., Hays, J., Mukherjee, S., Aranha, O., Iqbal, S., Shields, T., Benson, A. B., Kazmi, S., Lieu, C., Hochster, H., Whisenant, J., Haymaker, C., & Eng, C. (2026). NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. Journal of Clinical Oncology, 44(6), 497-507. https://doi.org/10.1200/jco-25-00929
Vancouver
Morris VK, Ciombor KK, Xiao L, Ochieng JK, Marmonti E, Polite B, et al. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. Journal of Clinical Oncology. 2026;44(6):497-507. doi:10.1200/jco-25-00929
BibTeX
@article{Morris2026,
author = {Morris, Van K and Ciombor, Kristen K and Xiao, Lianchun and Ochieng, Joshua K and Marmonti, Enrica and Polite, Blase and Weinberg, Benjamin A and Krauss, John C and Hays, John and Mukherjee, Sarbajit and Aranha, Olivia and Iqbal, Syma and Shields, Tony and Benson, Al B and Kazmi, Syed and Lieu, Christopher and Hochster, Howard and Whisenant, Jennifer and Haymaker, Cara and Eng, Cathy},
title = {NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {6},
pages = {497--507},
doi = {10.1200/jco-25-00929}
}
EUVIMED